Net institutional outflow of $5.33B. Sellers (650) massively outnumber buyers (493), with 164 complete exits. Insider activity data is absent, offering no counterweight.

Confirmation

Sustained net outflow next quarter will confirm the bearish distribution trend.

Invalidation Risk

A reversal in institutional flows or a cluster of insider buying would invalidate this verdict.

The above is AI-generated from public regulatory filings and summarizes historical data only. It is not investment advice and should not be used as the basis for any buy or sell decision.

Insider Trading (Form 4)

12-Month Buy/Sell Activity

Feb 25

BuySell

Action	Insider	Title	Date	Value
Sell	Newcomb George A.	Chief Accounting Officer	2025-02-18	$185K

View all insider trades →

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding GE HEALTHCARE TECHNOLOGY (GEHC)?

Major stakeholders currently include BlackRock, Inc. ($2.6B), Dodge & Cox ($2.2B), Vanguard Capital Management LLC ($2.1B). Based on the latest 13F filings, there are a total of 1252 tracked investment funds and institutions maintaining positions in GEHC.

What is the overall institutional sentiment toward GEHC recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $5.3B, driven by 494 managers accumulating shares while 650 reduced their exposure.

Which institutions have been selling or reducing their GEHC positions?

In the latest period, 486 funds trimmed their holdings, and 164 managers completely exited their positions. The aggregate reported sell value was $16.4B.

Are there any notable investors adding GEHC to their portfolios?

Yes, buying activity remains notable. 103 institutions opened new positions in {ticker}, and 391 existing holders added to their shares. The total reported buy value for the quarter amounted to $12.5B.